Diabetic retinopathy (early stage)
Also known as: Diabetic retinopathy - pre-proliferative, Diabetes, Diabetic
Methodology & AI Transparency ⓘ
Diabetic retinopathy (early stage) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Type 1 & Type 2 Diabetes diagnostic criteria (E11.3299), workup for Diabetic retinopathy (early stage) (also termed Diabetic retinopathy - pre-proliferative or Diabetes) integrates peripheral monofilament testing [Diabetic retinopathy (early stage) E11.3299] with evidence-graded therapy tailored to Hemoglobin A1c (HbA1c) [Diabetic retinopathy (early stage) E11.3299] response.
- 2 Real-world patient consensus: Synonyms for Diabetic retinopathy (early stage) (E11.3299): Diabetic retinopathy - pre-proliferative, Diabetes, Diabetic (Diabetes & Glucose).
- 3 Typical cash cost range: Workup highlights for Diabetic retinopathy (early stage) (E11.3299): peripheral monofilament testing [Diabetic retinopathy (early stage) E11.3299].
- 4 Top reported side effects / signs: Longitudinal Diabetic retinopathy (early stage) monitoring tracks Hemoglobin A1c (HbA1c) [Diabetic retinopathy (early stage) E11.3299] toward 4.8% – 5.6% (< 6.5% clinical target) (E11.3299).
Ask our AI Specialists anything about Diabetic retinopathy (early stage)
What Is Diabetic retinopathy (early stage)?
Under Type 1 & Type 2 Diabetes diagnostic criteria (E11.3299), workup for Diabetic retinopathy (early stage) (also termed Diabetic retinopathy - pre-proliferative or Diabetes) integrates peripheral monofilament testing [Diabetic retinopathy (early stage) E11.3299] with evidence-graded therapy tailored to Hemoglobin A1c (HbA1c) [Diabetic retinopathy (early stage) E11.3299] response.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Diabetic retinopathy (early stage) (E11.3299) center on unrestrained hepatic gluconeogenesis [Diabetic retinopathy (early stage) E11.3299]. targeted diabetes & glucose interventions aim to normalize Hemoglobin A1c (HbA1c) [Diabetic retinopathy (early stage) E11.3299].
Common Symptoms & Clinical Signs
- • Presentation of Diabetic retinopathy (early stage) (E11.3299): increased thirst [Diabetic retinopathy (early stage) E11.3299]
- • Secondary Diabetic retinopathy (early stage) clinical sign: postprandial afternoon energy in Diabetic retinopathy (early stage) (E11.3299: crashes and carbohydrate)
- • Symptom flares in Diabetic retinopathy (early stage) correlating with Hemoglobin A1c (HbA1c) [Diabetic retinopathy (early stage) E11.3299] deviation outside 4.8% – 5.6% (< 6.5% clinical target) (E11.3299)
- • Functional diabetes & glucose impact requiring peripheral monofilament testing [Diabetic retinopathy (early stage) E11.3299] evaluation (E11.3299)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Diabetic retinopathy (early stage) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E11.3299 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Diabetic retinopathy (early stage) E11.3299] | 4.8% – 5.6% (< 6.5% clinical target) (E11.3299) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Diabetic retinopathy (early stage) E11.3299] | 75 – 95 mg/dL (E11.3299) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Diabetic retinopathy (early stage) E11.3299] | 3.0 – 7.0 uIU/mL (E11.3299) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Diabetic retinopathy (early stage)
Treatment selection for Diabetic retinopathy (early stage) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diabetic retinopathy (early stage))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Real-world benefits and safety of liraglutide in the obese, non-diabetic: What a 4,754-Participant Study Found This systematic review and meta-analysis indicates that liraglutide to be an effective and safe treatment for weight loss in the obese, non-diabetic individuals. African health sciences • 2019-09-15 • Meta-Analysis | N = 4,754 | 99/100 | PMID 32127832 ↗ |
| New Insights on Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and: What a 14,059-Participant Study Found Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes. Obesity (Silver Spring, Md.) • 2026-06-15 • Meta-Analysis | N = 14,059 | 99/100 | PMID 41936548 ↗ |
| New Insights on Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone: What a 4,914-Participant Study Found High heterogeneity and diverse follow-up durations among studies were evident, which obscures the validity of the results. International journal of molecular sciences • 2024-07-22 • Meta-Analysis | N = 4,914 | 99/100 | PMID 39063229 ↗ |
| New Insights on Benefits and safety of anti-prediabetic drugs in patients with prediabetes: a: What a 16,610-Participant Study Found Among all the included interventions, GLP-1RAs, GIP/GLP-1RAs, and TZDs demonstrated favorable anti-prediabetic efficacy and acceptable safety. BMC medicine • 2026-02-19 • Meta-Analysis | N = 16,610 | 99/100 | PMID 41715123 ↗ |
| New Insights on A clinical trial in type 2 diabetic: What a 1,715-Participant Study Found This large-scale international trial should help define the clinical course and standards of care for hypertensive adults with type 2. American journal of kidney diseases : the official journal of the National Kidney Foundation • 2001-10-15 • Randomized Controlled Trial | N = 1,715 | 96/100 | PMID 11576953 ↗ |
Diabetic retinopathy (early stage) Patient Community & “People Like Me” Threads
Filter Diabetic retinopathy (early stage) community threads and patient logs by age, biological sex, dosage, and treatment duration.